<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5928">
  <stage>Registered</stage>
  <submitdate>10/12/2014</submitdate>
  <approvaldate>10/12/2014</approvaldate>
  <nctid>NCT02333331</nctid>
  <trial_identification>
    <studytitle>Dose Range Finding Study of Bimagrumab in Sarcopenia</studytitle>
    <scientifictitle>A 28 Week, Randomized, Double-blind, Placebo-controlled, Two-part, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia (InvestiGAIT)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CBYM338E2202</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sarcopenia</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - bimagrumab
Other interventions - placebo

Experimental: bimagrumab low dose - bimagrumab low dose infusion

Experimental: bimagrumab moderate dose - bimagrumab moderate dose infusion

Experimental: bimagrumab high dose - bimagrumab high dose infusion

Placebo Comparator: Placebo - Placebo infusion


Treatment: drugs: bimagrumab
Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.

Other interventions: placebo
Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Short Physical Performance Battery - Change from baseline to week 25.</outcome>
      <timepoint>Baseline, week 25</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability as assessed by various measures such as adverse events - Assessed by various measures such as adverse events over 24 weeks.</outcome>
      <timepoint>baseline, weeks 1, 5, 9, 13, 17, 21 and 25</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6-minute walk test - Change from baseline to week 25</outcome>
      <timepoint>baseline, week 25</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gait speed - Change from baseline to Week 25</outcome>
      <timepoint>baseline, week 25</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total lean body mass and appendicular skeletal muscle index measured by DXA - Change from baseline to Week 25</outcome>
      <timepoint>baseline, week 25</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Low muscle mass as confirmed by DXA;

          -  Low gait speed;

          -  SPPB score less than or equal to 9;

          -  Weigh at least 35 kg;

          -  Adequate dietary intake;</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  A lower limb fracture in the past 6 months or any impairment or disease severely
             affecting gait (e.g. stroke with hemiparesis, myasthenia gravis, Parkinson's disease,
             peripheral polyneuropathy, intermittent claudication in advanced peripheral vascular
             disease, spinal stenosis, or severe osteoarthritis of the knee or hip with ineffective
             pain management);

          -  Requires regular assistance from another person for general activities of daily living
             (e.g. bathing, dressing, toileting).

          -  Intraocular surgery and laser procedures for refractive correction within 6 months
             prior to screening;

          -  Any underlying muscle disease including active myopathy or muscular dytrophy;

          -  Confirmed diagnosis of heart failure classified as New York Heart Association Class
             III or IV (e.g. dilated cardiomyopathy);

          -  Type I diabetes or uncontrolled Type 2 diabetes;

          -  Chronic kidney disease [estimated glomerular filtration rate (GFR) &lt; 30 mL/min];

          -  History of confirmed chronic obstructive pulmonary disease with a severity grade &gt; 2
             on the Medical Research Council Dyspnea Scale;

          -  Confirmed rheumatoid arthritis or other systemic autoimmune disease requiring
             immunosuppressive therapy or corticosteroids &gt;10 mg/d prednisone equivalent;

          -  Known history or presence of severe active acute or chronic liver disease (e.g.,
             cirrhosis);

          -  Myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary
             intervention (e.g. angioplasty or stent placement), or deep vein thrombosis/pulmonary
             embolism within 12 weeks of screening;

          -  Active cancer (i.e., under current treatment), or cancer requiring treatment in the
             last 5 years excluding non-melanoma skin cancers or cancers with excellent prognosis
             (e.g., early stage prostate or breast cancer, carcinoma in situ of the uterine
             cervix);

          -  Any chronic active infection (e.g., HIV, Hepatitis B or C, tuberculosis, etc).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>9/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>280</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>13/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Adelaide</hospital>
    <hospital>Novartis Investigative Site - St Albans</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3021 - St Albans</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen NV</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuerzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gifu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saitama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokushima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castilla la Mancha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Gen√®ve 14</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the efficacy of repeat dosing with multiple dose
      levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older
      adults with sarcopenia. In addition, this study will generate data on the safety,
      tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02333331</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address />
      <phone>1-888-669-6682</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>